Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR3 | P29371 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL890232 | 1.00 | TACR3 (0.44) | TACR3ALDH1A1MTORMAPTMAPK1 | |
| SCHEMBL304497 | 0.87 | FPR2 (0.47) | ALDH1A1MTORMAPTMAPK1KMT2A | |
| SCHEMBL634437 | 0.87 | FPR2 (0.47) | ALDH1A1MTORMAPTMAPK1KMT2A | |
| SCHEMBL8912182 | 0.83 | MTOR (0.44) | ALDH1A1MTORMAPTMAPK1KMT2A | |
| SCHEMBL12463084 | 0.83 | HPGD (0.42) | TACR3ALDH1A1MTORPOLBKMT2A | |
| SCHEMBL8907649 | 0.81 | ALDH1A1 (0.45) | ALDH1A1MTORMAPTMAPK1POLB | |
| SCHEMBL10150894 | 0.81 | ALDH1A1 (0.41) | ALDH1A1MTORMAPTMAPK1POLB | |
| SCHEMBL18610229 | 0.81 | TACR3 (0.48) | TACR3ALDH1A1POLBKMT2AMTNR1A | |
| SCHEMBL890060 | 0.81 | TACR3 (0.48) | TACR3ALDH1A1POLBKMT2AMTNR1A | |
| SCHEMBL5744468 | 0.81 | TACR3 (0.48) | TACR3ALDH1A1POLBKMT2AMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110300104-A1 | HEPATITIS C VIRUS INHIBITORS | ENANTA PHARMACEUTICALS, INC. | 2011-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110300104-A1 | HEPATITIS C VIRUS INHIBITORS | HAVCR2, SLC10A1, EIF2AK2 | TACR3 4012/4885ALDH1A1 365/4885MTOR 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.